Literature DB >> 628197

Non-interaction of spironolactone medication and cortisol metabolism in man.

U Abshagen, S Spörl, M L'age.   

Abstract

In 5 healthy subjects and in 5 patients with decompensated liver diseases, the concentrations of cortisol, canrenone and canrenoate-K were determined after single doses and after a long-term treatment with spironolactone. The concentrations of the metabolites of spironolactone were determined fluorimetrically, those of cortisol by a highly specific radioimmunoassay with previous chromatographic separation. As a result, non-interaction between spironolactone medication and cortisol metabolism, even at high dose and long-term treatment conditions, was established neither in normal test subjects nor in patients with liver failure.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 628197     DOI: 10.1007/bf01478568

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  16 in total

1.  Spironolactone and cytochrome P-450: impairment of steroid hydroxylation in the adrenal cortex.

Authors:  R H Menard; H F Martin; B Stripp; J R Gillette; F C Bartter
Journal:  Life Sci       Date:  1974-11-01       Impact factor: 5.037

2.  Spironolactone and plasma cortisol.

Authors:  J S Dumlao; C Kannan; T Krauss; M H Brooks
Journal:  Clin Pharmacol Ther       Date:  1973 Nov-Dec       Impact factor: 6.875

3.  Radioimmunological determination of plasma cortisol.

Authors:  P Vecsei; B Penke; R Katzy; L Baek
Journal:  Experientia       Date:  1972-09-15

4.  Spironolactone and steroid assay.

Authors:  A O Lurie
Journal:  Lancet       Date:  1969-08-09       Impact factor: 79.321

5.  Fluorometric microassay for spironolactone and its metabolites in biological fluids.

Authors:  W Sadée; M Dagcioglu; S Riegelman
Journal:  J Pharm Sci       Date:  1972-07       Impact factor: 3.534

6.  Interference in the measurement of plasma 11-hydroxycorticosteroids caused by spironolactone administration.

Authors:  L C Wood; R Richards; S H Ingbar
Journal:  N Engl J Med       Date:  1970-03-19       Impact factor: 91.245

7.  Solid-phase radioimmunoassay of estradiol-17 beta.

Authors:  G E Abraham
Journal:  J Clin Endocrinol Metab       Date:  1969-06       Impact factor: 5.958

8.  Pharmacokinetics of spironolactone in man.

Authors:  U Abshagen; H Rennekamp; G Luszpinski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-12       Impact factor: 3.000

9.  Mechanism of action of spironolactone on adrenocortical function in guinea pigs.

Authors:  J W Greiner; R E Kramer; J Jarrell; H D Colby
Journal:  J Pharmacol Exp Ther       Date:  1976-09       Impact factor: 4.030

10.  Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment.

Authors:  U Abshagen; H Rennekamp; G Luszpinski
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

View more
  2 in total

1.  Interference of spironolactone therapy with adrenal steroid metabolism in secondary hyperaldosteronism.

Authors:  U Abshagen; S Spörl; M Schöneshöfer; M L'age; W Oelkers
Journal:  Klin Wochenschr       Date:  1978-04-01

2.  Displacement of cortisol from human heart by acute administration of a mineralocorticoid receptor antagonist.

Authors:  Javaid Iqbal; Ruth Andrew; Nicholas L Cruden; Christopher J Kenyon; Katherine A Hughes; David E Newby; Patrick W F Hadoke; Brian R Walker
Journal:  J Clin Endocrinol Metab       Date:  2013-01-01       Impact factor: 5.958

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.